Best Gene-Editing Stocks to Buy in 2025

Investing in Gene-Editing Stocks

By Keith Speights – Updated Sep 30, 2025 at 8:24 PM | Fact-checked by Frank Bass

Key Points

CRISPR technology, revolutionizing treatment of genetic diseases, offers long-term investment potential.
Intellia Therapeutics, co-founded by Nobel laureate Jennifer Doudna, progresses toward regulatory approval in gene therapies.
CRISPR Therapeutics, leading with FDA-approved gene-editing therapies, is expanding its treatment pipeline.

Genetic engineering, GMO and Gene manipulation concept. Hand is inserting sequence of DNA. 3D illustration of DNA. — Image source: Getty Images.

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
Intellia Therapeutics (NASDAQ:NTLA)	$2.7 billion	0.00%	Biotechnology
CRISPR Therapeutics (NASDAQ:CRSP)	$6.1 billion	0.00%	Biotechnology
Beam Therapeutics (NASDAQ:BEAM)	$2.8 billion	0.00%	Biotechnology

Data as of Oct 26, 2025.

Loading ticker_table...

Loading paragraph...

NASDAQ: NTLA

Intellia Therapeutics

Today's Change

(-1.12%) $-0.29

Current Price

$25.60

Key Data Points

Market Cap

$3B

Day's Range

$25.30 - $26.35

52wk Range

$5.90 - $28.25

Volume

Avg Vol

5.6M

Gross Margin

80.76%

Dividend Yield

N/A

Loading company_card...

Loading paragraph...

NASDAQ: CRSP

CRISPR Therapeutics

Today's Change

(0.59%) $0.40

Current Price

$67.61

Key Data Points

Market Cap

$6B

Day's Range

$66.85 - $68.71

52wk Range

$30.04 - $78.48

Volume

1.3M

Avg Vol

2.6M

Gross Margin

-24899.61%

Dividend Yield

N/A

Loading company_card...

Loading paragraph...

NASDAQ: BEAM

Beam Therapeutics

Today's Change

(-0.85%) $-0.24

Current Price

$27.96

Key Data Points

Market Cap

$3B

Day's Range

$27.42 - $28.71

52wk Range

$13.53 - $35.25

Volume

1.5M

Avg Vol

2.6M

Gross Margin

63.53%

Dividend Yield

N/A

Loading company_card...

Loading paragraph...

Related investing topics

Loading paragraph...

Investing in the Best Healthcare Stocks

Healthcare is a universal need. Companies in this broad-based sector can produce healthy returns.

Investing in Health Insurance Stocks

Health insurance is a necessity today, which means it's a great addition to your portfolio.

Investing in Biotech Stocks in 2025

These companies create drugs and treatments for some of the biggest medical problems of our time.

Investing in Pharmaceutical Stocks

The makers of the medicines that keep us happy and healthy can be great places to invest.

Loading paragraph...

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Investing in gene-editing stocks

CRISPR is based on the immune system that bacteria have developed to thwart viruses. The technique has been described as a “molecular scissor” honed in the battle of bacteria versus virus over millions of years. When attacked by a virus, bacteria are able to target, slice, and destroy the DNA of the virus.

In 2012, American biochemist Jennifer Doudna and French microbiologist Emmanuelle Charpentier studied the phenomena and discovered how CRISPR-associated (Cas) proteins could be used to slice strands of DNA. At the same time, RNA molecules made in a lab could guide Cas proteins to exactly where to cut the DNA. The technique works in any cell and opens the possibility for gene editing in humans, plants, and animals.

The door is now open for using gene editing as a “one-and-done” treatment for a wide range of deadly and debilitating genetic conditions.

In his New York Times best-seller The Code Breaker, author Walter Isaacson described CRISPR as changing "the future of the human race." (If you're unfamiliar with the book, you might start by watching The Motley Fool’s former healthcare bureau chief Corinne Cardina interview Isaacson on Fool Live.)

Both Intellia and CRISPR have found large pharmaceutical partners to help fund development and usher the new treatments to market.

Beam is pursuing innovations that meaningfully address some of the challenges and shortcomings in CRISPR-Cas9.

Many investors find gene-editing companies complicated. Other investors find them too volatile, with prices stagnating for long periods and then moving strongly up or down depending on publicity about new research findings or the outcome of clinical trials.

One approach for starting to invest in gene-editing stocks is to consider a basket strategy of putting money into several companies and watching them progress over several years.

Billions in market value will be created by companies with the ability to cure diseases.

For patient, buy-and-hold investors, gene-editing companies provide an opportunity to expand your portfolio during the coming genomic revolution.

Investing in Gene-Editing Stocks

Key Points

NASDAQ: NTLA

Key Data Points

NASDAQ: CRSP

Key Data Points

NASDAQ: BEAM

Key Data Points

Related investing topics

Investing in the Best Healthcare Stocks

Investing in Health Insurance Stocks

Investing in Biotech Stocks in 2025

Investing in Pharmaceutical Stocks

About the Author

Our Guides

Premium Investing Services

Is gene editing a good investment?

Which company is the leader in gene editing?

What stock is the king of genetic sequencing?

Do gene-editing companies typically pay dividends?

How do clinical trials affect gene-editing stock prices?

Best gene-editing companies to invest in

1. Intellia Therapeutics

2. CRISPR Therapeutics

3. Beam Therapeutics

Investing in gene-editing stocks

Related investing topics

How to buy gene-editing stocks

NASDAQ: NTLA

Key Data Points

NASDAQ: CRSP

Key Data Points

NASDAQ: BEAM

Key Data Points